Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Operations (2023 - 2025)

Monte Rosa Therapeutics' Cash from Operations history spans 3 years, with the latest figure at 43014000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 133.36% year-over-year to 43014000.0; the TTM value through Dec 2025 reached 22798000.0, down 154.29%, while the annual FY2025 figure was 22798000.0, 154.29% down from the prior year.
  • Cash from Operations reached 43014000.0 in Q4 2025 per GLUE's latest filing, down from 100428000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 128922000.0 in Q4 2024 to a low of 45492000.0 in Q1 2025.
  • Average Cash from Operations over 3 years is 2050333.33, with a median of 25015000.0 recorded in 2023.
  • The largest YoY upside for Cash from Operations was 578.37% in 2025 against a maximum downside of 133.36% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 29634000.0 in 2023, then surged by 335.05% to 128922000.0 in 2024, then tumbled by 133.36% to 43014000.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Cash from Operations are 43014000.0 (Q4 2025), 100428000.0 (Q3 2025), and 34720000.0 (Q2 2025).